A Phase II, Randomised Study to Assess the Pharmacokinetics, Safety and Pharmacodynamics of Single and Repeat Doses of RPL554 Administered by Pressurised Metered Dose Inhaler in Patients With COPD
Phase of Trial: Phase II
Latest Information Update: 18 Sep 2019
Price : $35 *
At a glance
- Drugs Ensifentrine (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Pharmacodynamics; Therapeutic Use
- Sponsors Verona Pharma
- 03 Jun 2019 Status changed from planning to recruiting, according to a Verona Pharma media release.
- 03 Jun 2019 According to a Verona Pharma media release, the company anticipates reporting data from the first part of the trial in the second half of 2019 and final data in the first quarter of 2020.
- 04 Mar 2019 According to a Verona Pharma media release, this study is expected to begin in second quarter of 2019.